A carregar...

Anti–PD-1 inhibitor–related pneumonitis in non–small cell lung cancer

The recent approval of two PD-1 inhibitors for the treatment of non–small cell lung cancer (NSCLC) has rapidly led to the widespread use of these agents in oncology practices. Pneumonitis has been recognized as a potentially life-threatening adverse event among NSCLC patients treated with PD-1 inhib...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Immunol Res
Main Authors: Nishino, Mizuki, Chambers, Emily S., Chong, Curtis R., Ramaiya, Nikhil H., Gray, Stacy W., Marcoux, J. Paul, Hatabu, Hiroto, Jänne, Pasi A., Hodi, F. Stephen, Awad, Mark M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4818710/
https://ncbi.nlm.nih.gov/pubmed/26865455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-15-0267
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!